drugset
drugset / Trial / NCT05086666

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

NCT05086666 ↗

Phase 1/2 Unknown 108 enrolled Abbisko Therapeutics Co, Ltd
NaSingle-groupOpen-labelTreatment

Summary

Phase 1b clinical study to evaluate the PK of oral AZD4547 in Chinese patients and RP2D. Phase 2 study to evaluate the efficacy of AZD4547 in urothelial carcinoma patients with FGFR2/3 gene alterations.

Timeline

Start
2021-06-03
Primary completion
2023-08-14
Completion
2024-05-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexagratinib Small molecule 80 mg Oral
Subject Fexagratinib Small molecule 120 mg Oral

Indications

urothelial carcinoma